Question · asked by 1 review
Polaprezinc vs Azulene: Oral mucositis (any severity)
- Population
- Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
- Intervention
- Polaprezinc
- Comparison
- Azulene
- Outcome
- Oral mucositis (any severity)
Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Polaprezinc vs Azulene Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies · Median 28 days Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported. Interventions for preventing oral mucositis for patients with cancer receiving treatment (2011) · Cochrane All outcomes | RR 0.82 [0.63, 1.06] | 1 study · 31 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes | 2011-02 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.